Newron Pharmaceuticals Shareholders Approve New Board Members at AGM 2026
Newron Pharmaceuticals' AGM 2026 approved the election of two independent directors, while extraordinary motions were postponed due to lack of quorum, highlighting shareholder dynamics.
Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) announced today that its shareholders approved all motions on the agenda for the ordinary part of the Annual General Meeting (AGM) 2026, including the election of George Garibaldi and Paolo Zocchi as new, independent, and non-executive Board members. However, the motions on the agenda for the extraordinary part of the meeting were not put to vote due to the required quorum not being reached.
The approval of the new directors marks a significant governance update for the biopharmaceutical company focused on therapies for central and peripheral nervous system (CNS) diseases. Chris Martin, Chairman of the Board, expressed gratitude to shareholders and welcomed the newly elected members, stating, "We welcome our newly elected Board members and are looking forward to their valuable inputs." He also thanked outgoing board members Patrick Langlois and Luca Benatti for their long-standing service.
The failure to achieve quorum for the extraordinary items suggests potential shareholder indecision or lack of engagement on certain strategic matters. This development may signal challenges in achieving consensus on key corporate actions, which could impact the company's future direction. Newron's lead compound, evenamide, a first-in-class glutamate modulator for treatment-resistant schizophrenia (TRS), is currently in the global pivotal ENIGMA-TRS Phase III program. Positive clinical results have shown significant improvements in efficacy measures and a favorable safety profile, which is uncommon for available antipsychotic medications.
The company has partnerships with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, and Myung In Pharm for South Korea. Its first marketed product, Xadago®/safinamide, approved for Parkinson's disease in multiple regions, is commercialized by partners Zambon, Supernus Pharmaceuticals, and Meiji Seika. For more information, visit www.newron.com.
The AGM results underscore the importance of shareholder support for governance changes and strategic initiatives. The inability to vote on extraordinary motions could delay potential corporate restructuring or capital measures, which may affect Newron's agility in advancing its pipeline. Investors and analysts will be watching closely for any rescheduled extraordinary meeting to understand the company's next steps.